ASGCT 25th Annual Meeting

ASGCT 25th
Annual Meeting

Expert talk

May 16-19, 2022
Washington, D.C.

My letter to Santa: wishes and reality impacting Cell and Gene therapies


Walter E. Washington Convention Center in Washington D.C.
Ballroom C
Booth 412


Tuesday 17 May 2022 from 17:30 to 19:00

During this round table, distinguished experts of the Cell and Gene Therapy field will lead a conversation and live Q&A aimed at deep diving into top science, technology and manufacturing trends of our industry.

The session will put together different expertise and points of view focusing on the challenges that this industry will be facing in the next future, and what their possible solutions could be.

Speakers’ Panel

Stefan Braam

CEO Ncardia and Cellistic

Stefan Braam brings Ncardia over a decade of experience in stem cell technology and product development. Before the appointment as CEO of Ncardia, Stefan was the CEO of Pluriomics being instrumental in the establishment and growth of the company.

Stefan won the NGI venture challenge (2009), the Niaba biobusiness Masterclass (2010), published in multiple leading scientific journals, is an inventor on multiple patent families, secured multiple grants and commercial research collaborations.

Nathalie Belmonte | Ph.D

SVP Research & Translation at Quell Therapeutics

Nathalie is SVP Research & Translation at Quell Tx, developing CAR-Treg therapy. Before joining Quell Tx, Nathalie served as COO at Promethera Biosciences developing MSC-based therapy.

Prior to that, she served as VP R&D at TxCell developing Treg cell-based therapy. She holds a PhD in Cell and Molecular Biology followed by a post-doctoral position at the Telethon Institute for Gene Therapy (TIGET) in Milan.

Jim Faulkner | Ph.D

Chief Technical Officer at Ascidian Therapeutics

Jim Faulkner is Chief Technical Officer at Ascidian Therapeutics – a Boston-based company redefining the treatment of genetic diseases by exon editing at the RNA level. In addition, Jim is a Venture Partner at AppleTree Partners (ATP), a leader in life sciences venture capital.

Jim is a highly experienced biopharmaceutical development leader with specialist skills in gene and cell therapy. Prior to his current roles, Jim headed Product Delivery for Autolus Ltd, a clinical-stage CAR-T company spun out of University College London.

Federico Mingozzi | Ph.D-MBA

Chief Scientific Officer at Spark Therapeutics

Dr. Federico Mingozzi is the Chief Scientific Officer of Spark Therapeutics. He spent several years at the Children’s Hospital Philadelphia (CHOP), in the United States, and the French National Institute of Health and Medical Research (INSERM) and Genethon, in France.

He served as faculty at the Pierre and Marie Curie University in Paris, France, and Universitat Autonoma de Barcelona, Spain. Throughout his career, he contributed to several preclinical and first-in-human clinical studies of gene therapy based on the AAV vector platform.

Alessandro Aiuti

Deputy director clinical research, San Raffaele Telethon Institute for gene therapy (SR-Tiget)

Professor Alessandro Aiuti is head of the Paediatric Immunohematology Unit at IRCCS San Raffaele Hospital in Milan as well as full professor of Paediatrics at Vita-Salute San Raffaele University and deputy director of the San Raffaele Telethon Institute for Gene Therapy (SR-Tiget).
Among his most relevant achievements, Professor Aiuti followed the clinical trials for ADA-SCID gene therapy, the first haematopoietic stem cell based gene therapy ever approved for commercialization.

Miguel Forte | MD-Ph.D

CEO at Bone Therapeutics
President-Elect ISCT, International Society for Cell & Gene Therapy

Miguel Forte is CEO of Bone Therapeutics, Professor at the Lisbon University and Board of Directors and Executive Committee member for ARM and Board Member for Essenscia-Wallonie.

President-Elect of ISCT from May 2022. Previously Chief Commercialization Officer and Chair of the ISCT Commercialization Committee (2014-2020) leading the expansion of the industrial community, strengthening the Committee to better represent the industrial translational objectives and needs of society membership.


Anthony Davies | Ph.D

Founder and CEO of Dark Horse Consulting

Anthony founded Dark Horse Consulting in 2014, bringing 20+ years of leadership experience in product, process and manufacturing development to cell and gene therapy companies in need.

Anthony has a proven track record in managing pharmaceutical pipelines, is a skilled liaison with international regulatory agencies, and has an intense familiarity with a wide range of biologics, and cell and gene therapies. He is a highly sought-after keynote speaker and chair of national and international conferences and seminars, noted for his provocative, thoughtful and sometimes contrarian presentations.

Stefano Baila | Ph.D

Director of Operations and BD at Anemocyte

Stefano received his PhD based on gene therapies research working at CHOP – Philadelphia.  Since then he has been actively involved in the process development and manufacturing of cell and gene therapy products through business development and strategic marketing roles at Areta International, a CDMO, and by leading field and commercialization activities for the cell processing unit at Terumo BCT.

tefano also worked as Industrialization Manager at Celyad where he led process development and automation efforts for CAR-T. Now he serves as Director of Operation and BD for Anemocyte.